Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Feb 17, 2019 - Amarin and Aphria could both be bought out soon.
Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Feb 07, 2019 - Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Feb 05, 2019 - The full year may be a different story.
Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Feb 02, 2019 - NVO earnings call for the period ending December 31, 2018.
Feb 01, 2019 - Novo Nordisk A/S (NYSE:NVO) Q4 2018 Earnings Conference Call February 1, 2019 7:00 AM ET Company Participants Lars Fruergaard Jørgensen – Chief Executive Officer Karsten Munk Knudsen – Chief Financial
Feb 01, 2019 - Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.